Allergan is recalling 12,699 bottles of Viokace (pancrelipase) 20,880 USP units tablets because the medication is subpotent. Stability testing revealed that the enzyme profile did not meet the required specifications, meaning the drug may not be as effective as intended for patients. These prescription tablets were distributed nationwide in 100-count bottles. Consumers should contact their healthcare provider or pharmacist to discuss treatment alternatives and how to return the product.
Because the medication does not contain the expected levels of active enzymes, it may fail to properly treat pancreatic insufficiency. This can lead to the malabsorption of nutrients and related digestive complications.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.